Serge E. Przedborski

Serge E. Przedborski's AcademicInfluence.com Rankings

Biology

#6079

World Rank

#8713

Historical Rank

Neuroscience

#718

World Rank

#750

Historical Rank

biology Degrees

Download Badge

Biology

Serge E. Przedborski's Degrees

Doctorate Medicine University of Buenos Aires
PhD Neuroscience University of Buenos Aires

Why Is Serge E. Przedborski Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Serge E. Przedborski's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Parkinson's Disease Mechanisms and Models (2003) (4794)
PINK1-dependent recruitment of Parkin to mitochondria in mitophagy (2009) (1449)
Oxidative Stress in Parkinson's Disease (2008) (1202)
Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease (2002) (1189)
Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons (2007) (1147)
Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice (2002) (1096)
Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease (1999) (1018)
Protocol for the MPTP mouse model of Parkinson's disease (2007) (807)
Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. (2000) (713)
Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration (2003) (626)
NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease (2003) (613)
Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. (1996) (610)
Toxin-induced models of Parkinson’s disease (2005) (606)
Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. (2008) (570)
Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. (1995) (559)
Neurological diseases: Targeting programmed cell death in neurodegenerative diseases (2003) (539)
Mitochondria: The Next (Neurode)Generation (2011) (514)
Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy (2017) (502)
Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. (1997) (501)
The parkinsonian toxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP): a technical review of its utility and safety (2001) (485)
Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP (2002) (478)
Classic and New Animal Models of Parkinson's Disease (2012) (470)
DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase (2007) (470)
Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease (2009) (466)
Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity (1992) (464)
Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinson’s Disease (2012) (461)
The Metabolic Topography of Parkinsonism (1994) (428)
Motor blocks in Parkinson's disease (1992) (417)
JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. (2004) (405)
VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. (1997) (403)
Rapamycin Protects against Neuron Death in In Vitro andIn Vivo Models of Parkinson's Disease (2010) (403)
Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). (1998) (397)
D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. (2003) (396)
α-Synuclein Is Localized to Mitochondria-Associated ER Membranes (2014) (394)
α‐Synuclein Up‐Regulation in Substantia Nigra Dopaminergic Neurons Following Administration of the Parkinsonian Toxin MPTP (2000) (390)
Parkinson’s disease: animal models and dopaminergic cell vulnerability (2014) (387)
Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. (1999) (368)
Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease (2001) (358)
Necroptosis Drives Motor Neuron Death in Models of Both Sporadic and Familial ALS (2014) (349)
Neurodegeneration: what is it and where are we? (2003) (348)
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations (2015) (331)
Freezing of gait in PD (2001) (328)
The role of glial cells in Parkinson's disease (2001) (326)
Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. (2004) (316)
The kinase domain of mitochondrial PINK1 faces the cytoplasm (2008) (314)
Nitrated α–Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons (2008) (314)
Spinal cord endoplasmic reticulum stress associated with a microsomal accumulation of mutant superoxide dismutase-1 in an ALS model. (2006) (313)
Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS (2002) (308)
Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease (2003) (300)
Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. (2005) (300)
Increased expression of the pro‐inflammatory enzyme cyclooxygenase‐2 in amyotrophic lateral sclerosis (2001) (290)
Early development of levodopa‐induced dyskinesias and response fluctuations in young‐onset Parkinson's disease (1991) (287)
Inhibition of Calpains Prevents Neuronal and Behavioral Deficits in an MPTP Mouse Model of Parkinson's Disease (2003) (286)
CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism (2005) (285)
MPTP as a Mitochondrial Neurotoxic Model of Parkinson's Disease (2004) (280)
Pathogenic role of glial cells in Parkinson's disease (2003) (277)
Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease (1995) (274)
Lack of Nigral Pathology in Transgenic Mice Expressing Human α-Synuclein Driven by the Tyrosine Hydroxylase Promoter (2001) (272)
Genetic clues to the pathogenesis of Parkinson's disease (2004) (265)
The 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Mouse Model (2003) (264)
Recruitment of the Mitochondrial-Dependent Apoptotic Pathway in Amyotrophic Lateral Sclerosis (2001) (259)
The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice (2006) (255)
Mass Spectrometric Quantification of 3-Nitrotyrosine, ortho-Tyrosine, and o,o′-Dityrosine in Brain Tissue of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated Mice, a Model of Oxidative Stress in Parkinson's Disease* (1999) (252)
Similar Patterns of Mitochondrial Vulnerability and Rescue Induced by Genetic Modification of α-Synuclein, Parkin, and DJ-1 in Caenorhabditis elegans* (2005) (252)
Ablation of the Inflammatory Enzyme Myeloperoxidase Mitigates Features of Parkinson's Disease in Mice (2005) (249)
The parkinsonian toxin MPTP: action and mechanism. (2000) (244)
The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. (1989) (239)
The two-century journey of Parkinson disease research (2017) (238)
Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease (2007) (223)
Neurodegeneration and inflammation in Parkinson's disease. (2012) (219)
Inducible Nitric Oxide Synthase Up‐Regulation in a Transgenic Mouse Model of Familial Amyotrophic Lateral Sclerosis (1999) (218)
Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration. (2001) (214)
Freezing of gait in PD: Prospective assessment in the DATATOP cohort (2001) (211)
Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson's disease. (2005) (207)
Neuromelanin Activates Microglia and Induces Degeneration of Dopaminergic Neurons: Implications for Progression of Parkinson’s Disease (2009) (202)
Enriched Environment Confers Resistance to 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine and Cocaine: Involvement of Dopamine Transporter and Trophic Factors (2003) (201)
Mechanisms of MPTP toxicity. (1998) (201)
The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway (2009) (191)
Oxidative post‐translational modifications of α‐synuclein in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) mouse model of Parkinson's disease (2001) (188)
COX‐2 and Neurodegeneration in Parkinson's Disease (2003) (187)
Pathogenesis of nigral cell death in Parkinson's disease. (2005) (183)
COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital (2021) (182)
Adaptive Immune Neuroprotection in G93A-SOD1 Amyotrophic Lateral Sclerosis Mice (2008) (181)
Human stem cell-derived spinal cord astrocytes with defined mature or reactive phenotypes. (2013) (180)
Clinical presentation and pharmacological therapy in corticobasal degeneration. (1998) (174)
Nitric Oxide and Reactive Oxygen Species in Parkinson's Disease (2003) (170)
Early differential diagnosis of Parkinson's disease with 18F‐fluorodeoxyglucose and positron emission tomography (1995) (169)
Pathogenesis of Parkinson's disease (2013) (168)
Neuroinflammation in glaucoma: A new opportunity (2017) (167)
Bax and Bcl‐2 Interaction in a Transgenic Mouse Model of Familial Amyotrophic Lateral Sclerosis (1999) (167)
The metabolic topography of idiopathic torsion dystonia. (1995) (167)
Programmed cell death in amyotrophic lateral sclerosis. (2003) (165)
Selectively enhanced contextual fear conditioning in mice lacking the transcriptional regulator CCAAT/enhancer binding protein delta. (1998) (164)
Delaying Caspase Activation by Bcl-2: A Clue to Disease Retardation in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis (2000) (164)
A novel mitochondrial 12SrRNA point mutation in parkinsonism, deafness, and neuropathy (2000) (161)
Metabolic correlates of levodopa response in Parkinson’s disease (2001) (160)
A tale on animal models of Parkinson's disease (2011) (158)
The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. (2003) (157)
Deciphering amyotrophic lateral sclerosis: What phenotype, neuropathology and genetics are telling us about pathogenesis (2013) (155)
α-Synuclein Overexpression Increases Cytosolic Catecholamine Concentration (2006) (155)
Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity (1993) (154)
Mitophagy: the latest problem for Parkinson's disease. (2011) (152)
MPTP: a review of its mechanisms of neurotoxicity (2001) (151)
D2-Like Dopamine Autoreceptor Activation Reduces Quantal Size in PC12 Cells (1998) (150)
Nitration and Inactivation of Tyrosine Hydroxylase by Peroxynitrite* (2001) (147)
Developmental cell death in dopaminergic neurons of the substantia nigra of mice (2000) (146)
Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats (1991) (145)
Mitochondrial autophagy in cells with mtDNA mutations results from synergistic loss of transmembrane potential and mTORC1 inhibition. (2012) (145)
Proteasome inhibition and Parkinson's disease modeling (2006) (143)
Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease (1993) (141)
Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients (2002) (137)
Differences in Nigral Neuron Number and Sensitivity to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 Mice (1994) (136)
Sonic Hedgehog Maintains Cellular and Neurochemical Homeostasis in the Adult Nigrostriatal Circuit (2012) (128)
Inflammation in ALS and SMA: Sorting out the good from the evil (2010) (126)
Creation of an Open-Access, Mutation-Defined Fibroblast Resource for Neurological Disease Research (2012) (126)
Mitochondrial Dynamics and Bioenergetic Dysfunction Is Associated with Synaptic Alterations in Mutant SOD1 Motor Neurons (2012) (125)
A Computational Model of Motor Neuron Degeneration (2014) (120)
Regulation of Dopaminergic Loss by Fas in a 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease (2004) (119)
The rotenone model of Parkinson's disease (2003) (115)
Cytosolic cleaved PINK1 represses Parkin translocation to mitochondria and mitophagy (2014) (106)
Adenosine receptor antagonists potentiate dopamine receptor agonist-induced rotational behavior in 6-hydroxydopamine-lesioned rats (1993) (103)
Superoxide Dismutase, Catalase, and Glutathione Peroxidase Activities in Copper/Zinc‐Superoxide Dismutase Transgenic Mice (1992) (103)
Multimodal Actions of Neural Stem Cells in a Mouse Model of ALS: A Meta-Analysis (2012) (102)
Brain superoxide dismutase, catalase, and glutathione peroxidase activities in amyotrophic lateral sclerosis (1996) (101)
Gene dosage and pathogenesis of Parkinson's disease. (2005) (99)
Identification of Neurodegenerative Factors Using Translatome-Regulatory Network Analysis (2015) (98)
Mitophagy and Parkinson's disease: Be eaten to stay healthy (2013) (94)
Instrumental Activation of Bid by Caspase-1 in a Transgenic Mouse Model of ALS (2002) (94)
Animal models of Parkinson's disease. (2012) (93)
Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression. (1999) (92)
α‐Synuclein expression in substantia nigra and cortex in Parkinson's disease (1999) (87)
Pink1 Kinase and Its Membrane Potential (Δψ)-dependent Cleavage Product Both Localize to Outer Mitochondrial Membrane by Unique Targeting Mode* (2012) (86)
Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases (2006) (86)
Fractalkine: moving from chemotaxis to neuroprotection (2006) (84)
Inflammation and Parkinson's disease pathogenesis (2010) (83)
Midbrain dopaminergic neuronal degeneration in a transgenic mouse model of familial amyotrophic lateral sclerosis (1997) (83)
α-Synuclein-Independent Histopathological and Motor Deficits in Mice Lacking the Endolysosomal Parkinsonism Protein Atp13a2 (2015) (80)
Positron emission tomography-guided stereotactic brain biopsy. (1992) (78)
Mitochondria, OxPhos, and neurodegeneration: cells are not just running out of gas. (2019) (75)
D-β-Hydroxybutyrate Is Protective in Mouse Models of Huntington's Disease (2011) (74)
Sequential activation of individual caspases, and of alterations in Bcl‐2 proapoptotic signals in a mouse model of Huntington's disease (2003) (70)
Effects of Wild‐Type and Mutated Copper/Zinc Superoxide Dismutase on Neuronal Survival and l‐DOPA‐Induced Toxicity in Postnatal Midbrain Culture (1997) (70)
The role of nitric oxide in Parkinson's disease. (2001) (67)
Prion protein codon 129 genotype prevalence is altered in primary progressive aphasia (2005) (66)
Lanosterol induces mitochondrial uncoupling and protects dopaminergic neurons from cell death in a model for Parkinson's disease (2011) (66)
Long-term behavioral and biochemical effects of 6-hydroxydopamine injections in rat caudate-putamen (1991) (66)
Effect of Unilateral Perinatal Hypoxic‐Ischemic Brain Injury in the Rat on Dopamine D1 and D2 Receptors and Uptake Sites: A Quantitative Autoradiographic Study (1991) (65)
A new role for α‐synuclein in Parkinson's disease: Alteration of ER–mitochondrial communication (2015) (62)
Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease. (2009) (61)
Programmed Cell Death in Amyotrophic Lateral Sclerosis: a Mechanism of Pathogenic and Therapeutic Importance (2004) (60)
Blood superoxide dismutase, catalase and glutathione peroxidase activities in familial and sporadic amyotrophic lateral sclerosis. (1996) (59)
Preparing a neurology department for SARS-CoV-2 (COVID-19) (2020) (59)
Brain-derived neurotrophic factor inhibits apoptosis and dopamine-induced free radical production in striatal neurons but does not prevent cell death (2001) (58)
The effect of stage of Parkinson’s disease at the onset of levodopa therapy on development of motor complications (2002) (58)
Promotion of mitochondrial biogenesis by necdin protects neurons against mitochondrial insults (2016) (57)
Neuroleptics Up‐Regulate Adenosine A2a Receptors in Rat Striatum: Implications for the Mechanism and the Treatment of Tardive Dyskinesia (1995) (57)
Metabolism of 3-Nitrotyrosine Induces Apoptotic Death in Dopaminergic Cells (2006) (56)
Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans (1995) (55)
Alpha-synuclein expression in substantia nigra and cortex in Parkinson's disease. (1999) (54)
PINK1/Parkin direct mitochondria to autophagy (2010) (54)
Neuroinflammation and Parkinson's disease. (2007) (53)
Role for VGLUT2 in selective vulnerability of midbrain dopamine neurons (2018) (52)
Mutant superoxide dismutase 1 (SOD1), a cause of amyotrophic lateral sclerosis, disrupts the recruitment of SMN, the spinal muscular atrophy protein to nuclear Cajal bodies. (2012) (51)
Experimental developments in movement disorders: update on proposed free radical mechanisms. (1998) (49)
Apoptosis‐inducing factor deficiency sensitizes dopaminergic neurons to parkinsonian neurotoxins (2010) (49)
Increased Superoxide Dismutase Activity Improves Survival of Cultured Postnatal Midbrain Neurons (1996) (48)
L‐3‐hydroxyacyl‐CoA dehydrogenase II protects in a model of Parkinson's disease (2004) (48)
Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6‐hydroxydopamine (2001) (47)
Novel subcellular localization for α-synuclein: possible functional consequences (2015) (47)
The impact of COVID-19 and social distancing on people with Parkinson’s disease: a survey study (2021) (45)
What can pluripotent stem cells teach us about neurodegenerative diseases? (2010) (45)
The Role of the Innate Immune System in ALS (2012) (45)
Positron emission tomographic findings in Filipino X‐linked dystonia–parkinsonism (1993) (44)
Hemiparkinsonism‐hemiatrophy syndrome (1990) (42)
Amelioration of the nigrostriatal pathway facilitated by ultrasound-mediated neurotrophic delivery in early Parkinson's disease. (2019) (41)
Antiparkinsonian therapies and brain mitochondrial complex I activity (1995) (41)
Sham transplantation protects against 6-hydroxydopamine-induced dopaminergic toxicity in rats: behavioral and morphological evidence (1991) (40)
Sleep EEG in depressed and nondepressed patients with Parkinson's disease. (1991) (39)
The Ubiquitination of PINK1 Is Restricted to Its Mature 52-kDa Form (2017) (39)
The Regulatory Machinery of Neurodegeneration in In Vitro Models of Amyotrophic Lateral Sclerosis. (2015) (38)
Randomized controlled phase II trial of glatiramer acetate in ALS (2006) (38)
Free radical and nitric oxide toxicity in Parkinson's disease. (2003) (38)
Nigrostriatal dopaminergic function in familial amyotrophic lateral sclerosis patients with and without copper/zinc superoxide dismutase mutations (1996) (37)
Positron emission tomography and histopathology in Creutzfeldt‐Jakob disease (1993) (34)
Unilateral MPTP-induced parkinsonism in monkeys. A quantitative autoradiographic study of dopamine D1 and D2 receptors and re-uptake sites. (1991) (33)
Bilateral modulation of [3H]neurotensin binding by unilateral intrastriatal 6-hydroxydopamine injections: evidence from a receptor autoradiographic study (1991) (32)
Metabolic topography of the hemiparkinsonism‐hemiatrophy syndrome (1994) (32)
PINK1 Content in Mitochondria is Regulated by ER-Associated Degradation (2019) (31)
Theophylline increases “on” time in advanced parkinsonian patients (1999) (31)
Neuroleptic medications inhibit complex I of the electron transport chain (1994) (31)
Reproducibility of monoamine metabolite measurements in human cerebrospinal fluid (1990) (31)
Non-cell-autonomous pathogenic mechanisms in amyotrophic lateral sclerosis (2021) (29)
Focused ultrasound enhanced intranasal delivery of brain derived neurotrophic factor produces neurorestorative effects in a Parkinson’s disease mouse model (2015) (28)
Glial cell response: A pathogenic factor in Parkinson’s disease (2002) (27)
A motif within the armadillo repeat of Parkinson’s-linked LRRK2 interacts with FADD to hijack the extrinsic death pathway (2018) (27)
Deletion of Ripk3 Prevents Motor Neuron Death In Vitro but not In Vivo (2019) (26)
The Postnatal Development of AMPA Receptor Subunits in the Basal Ganglia of the Rat (1998) (26)
Time course of the neuroprotective effect of transplantation on quinolinic acid-induced lesions of the striatum (1995) (26)
Effect of unilateral perinatal hypoxic-ischemic brain injury on striatal dopamine uptake sites and D1 and D2 receptors in adult rats (1991) (26)
Intrabody and Parkinson's disease. (2009) (25)
Quantitative assessment of quinolinic acid-induced striatal toxicity in rats using radioligand binding assays. (1994) (24)
Quinolinic acid-induced lesions of the rat striatum: quantitative autoradiographic binding assessment. (1998) (24)
Trichothiodystrophy, mental retardation, short stature, ataxia, and gonadal dysfunction in three Moroccan siblings. (1990) (23)
PINK1 points Parkin to mitochondria (2010) (22)
PARKINSON'S DISEASE: molecular and therapeutic insights from model systems (2017) (22)
The last decade in Parkinson's disease research. Basic sciences. (2001) (22)
Autoradiography of dopamine receptors and dopamine uptake sites in the spontaneously hypertensive rat (1990) (21)
Control of mitochondrial integrity in Parkinson's disease. (2010) (21)
A Sequel to the Tale of p25/Cdk5 in Neurodegeneration (2008) (21)
Cholecystokinin octa- and tetrapeptide degradation by synaptic membranes. III. Inactivation of CCK-8 by a phosphoramidon-sensitive endopeptidase (1984) (21)
Recent advances in amyotrophic lateral sclerosis research (2003) (21)
The effect of acute hemiplegia on intercostal muscle activity (1988) (20)
Isolated palsy of the superior branch of the oculomotor nerve due to chronic erosive sphenoid sinusitis. (1993) (19)
Erratum to “Instrumental activation of bid by caspase-1 in a transgenic mouse model of ALS” [Mol. Cell. Neurosci. 20 (2002) 553–562] (2003) (19)
Systematic elucidation of neuron-astrocyte interaction in models of amyotrophic lateral sclerosis using multi-modal integrated bioinformatics workflow (2020) (19)
A Computational Model of Motor Neuron Degeneration (2014) (18)
Recent Advances in the Development of Stem‐Cell‐Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease (2021) (18)
Randomized control trials in ALS: lessons learned (2004) (18)
Development of human neural transplantation. (1992) (17)
Brain glucose metabolism and dopamine D2 receptor analysis in a patient with hemiparkinsonism‐hemiatrophy syndrome (1993) (17)
Peroxiredoxin-2 links Cdk5 to neurodegeneration (2007) (16)
Mitophagy in cells with mtDNA mutations (2012) (16)
Glutamate pathway implication in amyotrophic lateral sclerosis: what is the signal in the noise? (2010) (15)
Fentanyl‐induced dyskinesias (1995) (15)
Slow increase of homovanillic acid in cerebrospinal fluid after levodopa administration (1996) (15)
Role for VGLUT 2 in selective vulnerability of midbrain dopamine neurons (2019) (14)
The MPTP Model of Parkinson’s Disease (2007) (14)
Partial attenuation of chronic fluphenazine-induced changes in regional monoamine metabolism by D-α-tocopherol in rat brain (1991) (14)
Is prostaglandin E2 a pathogenic factor in amyotrophic lateral sclerosis? (2006) (14)
Effect of Unilateral Perinatal Hypoxic‐Ischemic Brain Injury in the Rat on Striatal Muscarinic Cholinergic Receptors and High‐Affinity Choline Uptake Sites: A Quantitative Autoradiographic Study (1991) (14)
Engineered modeling and the secrets of Parkinson's disease (2001) (14)
SARS-CoV-2 Infection Causes Dopaminergic Neuron Senescence (2021) (14)
5th International Symposium on Focused Ultrasound (2016) (13)
Loss of ROS—a radical response (1998) (13)
Positron emission tomography in hemiparkinsonism-hemiatrophy syndrome. (1993) (13)
Discussion of Research Priorities for Gait Disorders in Parkinson's Disease (2021) (12)
Induction of mania by apomorphine in a depressed Parkinsonian patient (1992) (12)
Resistance of SOD-Transgenic Mice to Oxidative Stress (1992) (11)
Axonal Degeneration: RIPK1 Multitasking in ALS (2016) (11)
Lack of efficacy of phenytoin in the syndrome of inappropriate anti-diuretic hormone secretion of neurological origin. (1989) (11)
Is there a pathogenic role for mitochondria in Parkinson's disease? (2009) (10)
Pathogenic Lrrk2 substitutions and Amyotrophic lateral sclerosis (2007) (10)
Decrease of vasoactive intestinal peptide, methionine-enkephalin, substance P and increase of neuropeptide Y immunoreactive nerve fibres in aganglionic colon of Hirschsprung's disease (1989) (10)
Inflammatory demyelinating polyradiculoneuropathy associated with human immunodeficiency virus infection (1988) (10)
Neurotensin high affinity binding sites and endopeptidase 24.11 are present respectively in the meningothelial and in the fibroblastic components of human meningiomas (1990) (10)
Quantitative autoradiographic distribution of [3H]mazindol-labeled dopamine uptake sites in the brains of superoxide dismutase transgenic mice (1990) (10)
Nervous system manifestations and neuroradiologic findings in acquired immunodeficiency syndrome (AIDS) (2004) (9)
Neurodegenerative Diseases: Toxic animal models (2005) (9)
Engineered modeling and the secrets of Parkinson's disease (2001) (9)
Is prostaglandin E(2) a pathogenic factor in amyotrophic lateral sclerosis? (2006) (9)
Quantitative autoradiographic distribution of [3H]-MPTP binding in the brains of superoxide dismutase transgenic mice (1991) (9)
Lack of changes in ventricular cerebrospinal fluid concentrations of homovanillic acid following acute challenge with levodopa (1992) (9)
Targeting α -synuclein for treating Parkinson’s disease: mechanistic and therapeutic considerations (2017) (9)
Is Amyotrophic Lateral Sclerosis a Mitochondrial Channelopathy? (2010) (8)
Cholecystokinin distribution in the human striatum and related subcortical structures (1989) (8)
Neurotensin receptors in human meningiomas (1991) (7)
Focused-ultrasound Mediated Anti-Alpha-Synuclein Antibody Delivery for the Treatment of Parkinson's Disease (2017) (6)
COVID-19 manifestations in people with Parkinson’s disease: a USA cohort (2021) (6)
Addressing the Challenges of Clinical Research for Freezing of Gait in Parkinson's Disease (2021) (6)
Pink1 and its Δψ -dependent cleavage product both localize to the outer mitochondrial membrane by a unique targeting mode* (2012) (6)
Autoradiographic evidence of [3H]neurotensin binding changes in discrete regions of brain in the rat model of persistent spasmodic dyskinesia induced by iminodipropionitrile (1989) (6)
Variations of homovanillic acid levels in ventricular cerebrospinal fluid (1992) (6)
Systemic and intrastriatal theophylline have opposite effects on dopamine and dopamine metabolites measured by intrastriatal microdialysis in the rat (1996) (6)
Molecular targets for neuroprotection (2004) (6)
From Man to Mouse: The MPTP Model of Parkinson Disease (2015) (6)
Delayed-onset dyskinesias (1996) (5)
| Amyotrophic Lateral Sclerosis | Taylor & Francis Group (2005) (5)
Regional changes in brain 5-HT1A serotonin receptors in the rat model of persistent spasmodic dyskinesias induced by iminodipropionitrile (1989) (5)
Sumoylation regulates the assembly and activity of the SMN complex (2021) (5)
The MPTP Mouse Model of Parkinson's Disease: the True, the False, and the Unknown (2008) (5)
When Schwann Cells Conspire with Mitochondria, Neighboring Axons Are under Attack by Glia-Derived Neurotoxic Lipids (2013) (4)
Role of Nitric Oxide in MPTP Induced Dopaminergic Neuron (2000) (4)
Quantitative autoradiographic changes in 5-[3H]HT-labeled 5-HT1 serotonin receptors in discrete regions of brain in the rat model of persistent dyskinesias induced by iminodipropionitrile (IDPN) (1990) (3)
Does increased superoxide dismutase activity really cause muscular dystrophy? (1999) (3)
Clarification: Pathogenic role of glial cells in Parkinson's disease (2004) (3)
Mitochondrial dysfunction and neurodegenerative disorders (2006) (3)
Neuropeptide Y, somatostatin, and cholecystokinin neurone preservation in anaplastic astrocytomas (2004) (3)
Pathogenic Lrrk 2 substitutions and Amyotrophic lateral sclerosis (2007) (3)
Transgenic superoxide dismutase overproducer: murine. (2002) (2)
Advances in our Knowledge of MPTP Action and Mechanism (2000) (2)
Effect of HECNU in malignant supratentorial gliomas — a phase II study (1988) (2)
Motoneuron Diseases. (2022) (1)
Therapeutic immunization protections dopaminergic neurons in a mouse model of Parkison's disease (2004) (1)
Lipid level alteration in human and cellular models of alpha synuclein mutations (2022) (1)
MPTP and Oxidative Stress: It’s Complicated! (2011) (1)
Parkinson's disease : a subject collection from Cold Spring Harbor perspectives in meicine (2012) (1)
A case of late onset striatonigral degeneration. (1989) (1)
Neuroprotection and neuroregeneration triggered through the FUS-induced opening of the blood-brain barrier in a Parkinson’s mouse model (2015) (1)
Retromer dysfunction in amyotrophic lateral sclerosis (2022) (1)
Can we reverse alpha‐synuclein lesions? (2011) (1)
Visualization of neuropeptides and neurotransmitters in the human brain. Applications to development and pathology.: Werner Gren International Symposium Series 45, pp 31-40 (1988) (1)
[Current therapeutic approach in Parkinson disease]. (1992) (1)
3.14.1 MICROGLIA AND NEUROINFLAMMATION IN PD (2012) (1)
Chapter 14 Cell Death Pathways in Amyotrophic Lateral Sclerosis (2003) (0)
TITLE : Interaction of Synuclein and inflammation in Dopaminergic Neurodegeneration PRINCIPAL INVESTIGATOR : (2009) (0)
Interaction of Synuclein and Inflammation in Dopaminergic Neurodegeneration (2010) (0)
Dysfunction of mitochondrial oxidative phosphorylation in als rat model (2007) (0)
Time course of the protective effect of transplantation on quinolinic acid-induced striatal lesion (1994) (0)
Alpha‐tocopherol levels in Parkinsonian brains (1993) (0)
Molsidomide provides neuroprotection against vincristine-induced peripheral neurotoxicity (2019) (0)
Gordon, P. H. et al. Randomized controlled phase II trial of glatiramer acetate in ALS. Neurology 66, 1117-1119 (2006) (0)
Short Communication Pathogenic Lrrk2 substitutions and Amyotrophic lateral sclerosis (2007) (0)
3.205 NECDIN PREVENTS LOSS OF DOPAMINERGIC NEURONS IN ANIMAL MODELS OF PARKINSON'S DISEASE (2012) (0)
Role of Inflammation in MPTP-Induced Dopaminergic Neuronal Death (2008) (0)
Drug may put brakes on Parkinson's disease (2009) (0)
NEURONAL PROTECTION AGAINST EXCITOTOXICITY. AUTHOR'S REPLY (1993) (0)
O.020 Is there a pathogenic role for mitochondria in PD (2009) (0)
Reply to: “Letter on Discussion of Gait Research” (2022) (0)
AComputationalModel ofMotorNeuronDegeneration (2016) (0)
Pre-Clinical Testing of New Hydroxybutyrate Analogues (2011) (0)
DELAYED-ONSET DYSKINESIA. AUTHOR'S REPLY (1996) (0)
3.260 D-β-HYDROXYBUTYRATE IS NEUROPROTECTIVE IN MOUSE MODELS OF HUNTINGTON'S DISEASE (2012) (0)
The Ubiquitination of PINK 1 Is Restricted to Its Mature 52-kDa Form Graphical Abstract Highlights (2017) (0)
Cholecystokinin immunoreactivity and binding sites in hippocampal formation, striatum including related subcortical structures, brain stem and cerebellum of the human brain.: In: The Neuropeptide cholecystokinin (CCK). Anatomy and biochemistry receptors, pharmacology and physiology. pp 109-116 (1989) (0)
The impact of COVID-19 and social distancing on people with Parkinson’s disease: a survey study (2021) (0)
Lackofefficacy ofphenytoin inthesyndrome ofinappropriate anti-diuretic hormone secretion ofneurological origin (1989) (0)
Preface (2004) (0)
NEURORESTORATION OF THE DOPAMINERGIC PATHWAY USING FOCUSED ULTRASOUND-MEDIATED PROTEIN AND GENE DELIVERY IN A PARKINSONIAN MODEL (2018) (0)
Role of Inflammation in MPTP-Induced Dopaminergic Degeneration (2005) (0)
Neuroprotective Small Molecules for the Treatment of Amyotrophic Lateral Sclerosis (2012) (0)
Experimental Models of Motor Neuron Diseases (2005) (0)
Astrocyte mediated toxicity leads to motor neuron death in Spinal Muscular Atrophy (S17.006) (2015) (0)
Focused Ultrasound Enhanced Intranasal Delivery of Neurotrophic Factors Exhibit Neurorestorative Effects in Parkinson's Disease Mouse Model (2018) (0)
The Interaction of Astrocytes and Motor Neurons in ALS (2009) (0)
3.7.3 ANIMAL MODELS OF PD (2012) (0)
Toxicity of the specific antimuscarinic agent methoctramine and other non-specific anticholinergic drugs in human neuroblastoma cell lines in vitro. (1993) (0)
New insights into the pathophysiology of dystonia (2011) (0)
Lipid level alteration in human and cellular models of alpha synuclein mutations (2022) (0)
Visualization of neuropeptides and neurotransmitters in the human brain. Applications to development and pathology.: Proceedings of the WENNER-GREN Conference on "Visualization of brain function" held at Stockholm, 1988. vol. 53, pp 31-40 (1989) (0)
Functional Neural Transplantation. Edited by Stephen B. Dunnett and Anders Björklund. New York: Raven Press, 1994, 608 pp. Price: $145.00 (1996) (0)
Clinical presentation and pharmacological therapy in cortico-basal ganglionic degeneration (1996) (0)
Contents page + Editorial Board (2003) (0)
A motif within the armadillo repeat of Parkinson’s-linked LRRK2 interacts with FADD to hijack the extrinsic death pathway (2018) (0)
Decision letter: Mitochondrial fusion is required for spermatogonial differentiation and meiosis (2019) (0)
Reply (1996) (0)
Program Project on the Pathogenesis and Treatment of Parkinson's Disease (2004) (0)
Neuronal protection against excitotoxicity. (1993) (0)
c-jun-N-Terminal Kinase (JNK) for the Treatment of Amyotrophic Lateral Sclerosis (2015) (0)
[Pathogenesis and treatment of multiple sclerosis. Review and personal results]. (1988) (0)
Role of Nitric Oxide in MPTP-Induced Dopaminergic Neuron Degeneration (2004) (0)
Can a defect in bioenergetics be involved in the pathogenesis of Parkinson's disease after all? (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Serge E. Przedborski?

Serge E. Przedborski is affiliated with the following schools: